Junshi Biological (1877cherryjackpotcasinonodepositbonus.HK) rose by more than 5%cherryjackpotcasinonodepositbonus, is now quoted at HK$10.22, and the total market value has returned to HK$10 billion. Junshi Biotech's A shares are currently up 4% to 25.79 yuan. On the news, the company received a notice from the Drug Office (DO) of the Hong Kong Department of Health that the marketing authorization application for terreprimab (product code: TAB001/JS001) combined with cisplatin/gemcitabine has been accepted as the first-line treatment of adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as a monotherapy for adult patients with recurrent, unresectable or metastatic nasopharyngeal carcinoma who have progressed during or after previous platinum-containing therapy.